Abstract: Inequities in the incidence of HIV infection and AIDS with continued persistence of HIV-associated neurocognitive disorders (HAND) exist in populations in Hawaii (HI) and Puerto Rico (PR). We previously reported that peripheral monocyte HIV DNA levels are high in patients in Hawaii with HAND and we now hypothesize that similar fi ndings would be observed in the cerebrospinal fl uid (CSF) cellular subsets. Cerebrospinal fl uid cells were obtained from patients from PR and HI undergoing neurocognitive testing and sorted into monocytes (CD14+) and lymphocytes (CD14-) and HIV DNA was measured. From six PR subjects (three HAND, three normal cognition, NC) and six HI subjects (three HAND, three NC), HIV DNA burden in CD14+ cells was higher in HAND than NC patients; NC patients had higher HIV DNA burden in CD14-cells versus HAND. Diff erences in HIV DNA burden in particular CSF cellular subsets suggest that HIV DNA burden may play a role in HAND neuropathogenesis.
I
n the United States, inequities in the incidence and prevalence of human immunodefi ciency virus (HIV)-infection amongst ethnic minorities are well recognized 1, 2 Because there are potential diff erences in access and adherence to combined antiretroviral therapy (cART), 3 there may be diff erences in clinical status regarding neurocognition that might be observed in some segments of the population. [4] [5] [6] In spite of advancements made in improving the prognosis of HIV/AIDS, prevalence of HAND (HIV Associated Neurocognitive Disorder) continues to persist. 7 This continued presence of HAND suggests that even with eff ective cART, other factors may be infl uencing neuropathogenesis.
Increasing reports support the hypothesis that chronic neuroinfl ammation may be present throughout the course of HIV infection even with eff ective cART. [8] [9] [10] Early in the HIV epidemic, percentages of a unique population of activated monocytes (CD14+/16+ phenotype) were noted to be elevated in subjects with HIV-associated neurocognitive disorder (HAND). 11 Monocytes were known to be a site of latent HIV-infection and activated monocytes were known to be permissive to HIV-infection, [12] [13] [14] but Neuenburg et al. also observed increased percentages and numbers of activated monocytes in cerebrospinal fl uid (CSF) from HIV-infected patients receiving cART. 15 In other studies, where CSF production is known to originate from the choroid plexus, monocytes were shown to traffi c to the choroid plexus stroma and perivascular spaces, where many of the infi ltrating monocytes in the choroid plexus were activated. [16] [17] [18] [19] Cerebrospinal fl uid monocytes are known to have slower CSF-compartmentalized variant viral decay in patients with HAND. Therefore, we hypothesized that CSF monocytes may be important in neuropathogenesis of HAND. 20 Recently cART penetration into the CSF compartment has been suggested as a factor in HAND persistence described as the CNS (Central Nervous System) penetration eff ect (CPE) score. 21 We examined HIV DNA levels in CSF cells to determine if diff erences exist between the CSF cellular subsets, which might provide insight into the role of viral DNA in the neuropathogenesis of HAND.
Methods
Patient cohorts and specimens. The study was designed based on convenience samples of two existing cohorts characterizing HAND in Hawaii (HI) and Puerto Rico (PR). The Hispanic/Latino Longitudinal NeuroAIDS Cohort of HIV-seropositive women from the University of Puerto Rico Medical Sciences Campus (PR) enrolled HIV-1-infected Puerto Rican women according to guidelines approved by the local Institutional Review Board (IRB). These women were at least 18 years of age, had CD4+ T lymphocyte counts of ≤500, had at least a 9th grade education, and showed no evidence of either active systemic infection or neurodegenerative disease. 6 Patients from the Hawaii Aging with HIV Cohort from the University of Hawaii (HI) were living in Hawaii; were between ages of 20-30 years old, or 50 years old or older without any of the following: history of head injury, learning disability, major neurologic/psychiatric disease, or opportunistic brain disease; and were enrolled in the cohort according to guidelines by the local IRB. 22 Puerto Rican and Hawaiian subjects underwent a macroneurological exam and neurocognitive testing as previously described. 6, 22 They each had baseline evaluations that included medical history, risk behavior inventory, plasma and CSF viral levels (CLIA-certifi ed clinical laboratory), CD4 count, nadir CD4 count, medication history, and co-morbid illnesses. 6, 22 Upon entry into the cohort, subjects who consented to have a lumbar puncture (LP) performed had CSF (10 mL) processed for viably-preserved cells and stored in PBS containing dimethyl sulfoxide (DMSO). The current study was designed as a cross-sectional study to assess HIV DNA in CSF cellular subsets.
HIV-associated neurocognitive disorder assessment. Cognitive function was determined using the American Academy of Neurology HIV dementia criteria (1991) as previously described. 6, [22] [23] [24] For the current study, subjects were divided into normal cognition (NC) and HAND, which included minor cognitive motor disorder and HIVassociated dementia. 6, [22] [23] [24] Fluorescent activated cell sorting (FACS). Frozen CSF cells were thawed in 100% fetal bovine serum (FBS), treated for 10 minutes with Accumax (Innovative Cell Technologies, Inc., San Diego, CA) and fi ltered through a 30 μm CellTrics fi lter (Partec, Germany). Cells were then immediately fl uorescently labeled with the following antibodies: CD3-PerCp/Cy5.5 and CD14-FITC (BD Biosciences, San Jose, CA) for 20 minutes at room temperature, washed with 2% FBS, PBS and fi xed with a 2% paraformaldehyde (PFA) solution. Aft er fi xation, the cells were diluted with PBS and underwent cell sorting using the FACSAria (BD Biosciences, San Diego, CA) into the cell subsets: non-monocytes (CD14-) and monocytes (CD14+). The acquisition protocol gated on CD14+ and CD14-, Figure 1 . The cells were sorted directly into lysis buff er in preparation for DNA extraction.
HIV DNA quantifi cation. DNA was extracted from the CSF cellular subsets using the QIAamp DNA Micro Kit (Qiagen, Valencia, CA) as per guidelines by the manufacturer and eluted in 20 цL TE buff er. HIV DNA copy numbers in each of the CSF cellular subsets were assessed as previously described 25 to obtain the amount of HIV DNA copies per cell. The total CSF HIV DNA burden was determined by multiplying the HIV DNA per cell by the total CSF subset cell count based on the number of events during the sort and isolated for each CSF cell fraction. The CNS penetration eff ect (CPE) score was calculated based on guidelines set by Letendre et al. 21, 26 to determine how eff ective the drug regimen was in crossing the blood/brain barrier.
Statistics. Median total HIV DNA/CSF cell fraction was calculated using SAS software (copyright SAS Institute Inc. SAS and all other SAS product or service names are registered trademarks of SAS Institute Inc., Cary, NC, USA). Spearman's correlations for the CPE scores and total amount of HIV DNA in the CSF cellular subsets were determined using SPSS 13.0. A p value <.05 was considered signifi cant. Graphs were generated using GraphPad Prism 5 (GraphPad Soft ware, La Jolla, CA, USA). Table 1 . The six PR subjects were diagnosed with HAND (n=three) or NC (n=three); the six HI subjects were diagnosed with HAND (n=three) or NC (n=three). With the exception of patients PR6, all patients were on cART at the time of the LP. No signifi cant diff erences were observed among the cohort characteristics except that the PR cohort included only women due to its design (p=.02). The majority of the CSF specimens had relatively low CSF WBC (nine of 12) with only three (PR4, PR6, H6) subjects having mild CSF pleocytosis, defi ned as CSF WBC ≤ 50 cells/mm 3 . Overall, most subjects (nine of the 12 subjects) had concordant undetectable plasma and CSF viral levels.
HIV DNA. The HIV DNA results from the patients demonstrated an overall total median HIV DNA burden that was higher in CSF CD14+ cells in HAND individuals than in those with NC; 141.1 versus 100.1 HIV DNA copies, Table 2 . In contrast, individuals with NC had higher median HIV DNA burden in CSF 14-cells than those with HAND; 543.3 versus 79.1 copies, Table 2 .
Positive correlations were observed between total HIV DNA and CNS penetration eff ect (CPE) [21, 26] The total median HIV DNA of the combined CD14+ and CD14-subsets was higher in the PR patients than in the HI patients (data not shown), suggesting that diff erences may exist between the cohorts; however the small sample size precludes any signifi cant conclusion.
Discussion
We report for the fi rst time diff erences in HIV DNA copy numbers from CSF monocytes compared with CSF lymphocytes from two cohorts of patients from HI and PR. However, because the data are based on a limited number of specimens, conclusions related to HIV DNA and CSF cellular subsets cannot be drawn. Our fi ndings provide a foundation and feasibility data that HIV DNA can be measured from cellular subsets, which could be used as a tool to address mechanisms for HAND in the future. Previously, we demonstrated that HIV DNA levels were high in monocytes and peripheral blood mononuclear cells in patients with HAND and remained high while on cART. Because these circulating monocytes can traffi c to the BBB (Blood-Brain Barrier) and infi ltrate the choroid plexus where CSF production occurs, the implication that these cellular subsets might also have diff erent HIV DNA copy numbers might suggest a role in neuropathogenesis. [16] [17] [18] [19] Adhesion molecules (E-selectin and P-selectin) and increased cytokine production (MCP-1) are thought to be involved in leukocyte recruitment into CSF=Cerebrospinal Fluid the choroid plexus. 18, 27, 28 Once through the blood/brain barrier via monocytes, HIV-1 is then transported into the choroid plexus and into the CSF. Studies on viral evolution suggest that cellular compartmentalization within the CSF provides an environment for the CSF to serve as a unique reservoir for cells with latent virus, which may contribute to viral persistence in the CNS. 20, [29] [30] [31] [32] [33] [34] These reservoirs may be unaff ected by cART as demonstrated by the positive correlation between cART CPE and total HIV DNA which may be a mechanism by which the virus evades eradication. The identifi cation of T cell-tropic and macrophage-tropic HIV-1 variants in the CSF of individuals with HAND may provide an explanation to the diff erences observed in CD14-and CD14+ HIV DNA levels in HAND and NC individuals.
A limitation of the study was the small number of specimens available. However, the high HIV DNA copies in CSF monocytes in HAND patients from both cohorts suggests that CSF monocytes may represent a viral reservoir in the CSF leading to viral persistence. Future studies with larger sample sizes are planned to verify our preliminary fi ndings and to look into contributing factors for any diff erences that occur between the two cohorts. The effi cacy and mechanisms of controlling HIV infection in the Cerebrospinal fl uid viral reservoirs may play a role in HAND pathogenesis because latent cells upon activation are able to maintain low levels of viral replication. Others have suggested that CSF compartmentalization develops because these reservoirs exist in the CSF and harbor HIV variants. 20 Therefore, we hypothesize that infi ltrating monocytes, particularly activated monocytes (CD14+/16+) from the choroid plexus, could contribute to the infl ammatory milieu. In parallel, HIV DNA levels in the non-activated monocytes (CD14+/16-) may represent latent viral reservoirs that allow the virus to evolve. Further characterization of the CSF cellular subsets is necessary to determine the signifi cance of HIV DNA in this compartment as it relates to neuropathogenesis. Correlation between CNS penetration eff ect (CPE) score and the total HIV DNA in CD14 negative (p=0.010) and positive cells (p=0.034); suggesting that an antiviral regimen consisting of drugs that penetrate the CNS (high CPE score) may not necessarily impact the HIV DNA copy numbers in the CSF cells.
